Vaxcyte, Inc. (PCVX) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Vaxcyte, Inc. (PCVX) trades at $56.20 with AI Score 53/100 (Grade B). Vaxcyte, Inc. is a clinical-stage biotechnology company focused on developing novel protein vaccines for bacterial infectious diseases. Market cap: $8.12B, Sector: Healthcare.
Price as of Jul 20, 2026 · Last analyzed: May 10, 2026PCVX stock analysis for 2026: Analysts have set a consensus price target of $89.00 for Vaxcyte, Inc., suggesting 58.4% upside from the current price of $56.20. The AI MoonshotScore is 53/100, indicating a neutral outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
PCVX: 2/3 scored disciplines lean bearish. Dominant signal: Ken Griffin bearish.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Vaxcyte, Inc. (PCVX) Healthcare & Pipeline Overview
Vaxcyte, Inc. is a clinical-stage biotechnology company specializing in novel protein vaccines, with a primary focus on combating bacterial infectious diseases. Their lead candidate, VAX-24, a 24-valent pneumococcal conjugate vaccine, is currently in Phase 1/2 clinical trials, positioning the company to address the significant unmet needs in preventing pneumococcal diseases.
What Is the Investment Thesis for PCVX?
Vaxcyte's investment thesis centers on its innovative vaccine technology and its potential to address significant unmet needs in the prevention of bacterial infectious diseases. The lead candidate, VAX-24, shows promise in providing broader coverage against pneumococcal disease compared to existing vaccines. Positive Phase 1/2 clinical trial data could serve as a major catalyst, driving investor confidence and potentially leading to partnerships or acquisitions. The company's pipeline, including VAX-XP, VAX-A1, and VAX-PG, offers further growth opportunities by targeting additional infectious diseases. However, the company faces risks associated with clinical trial outcomes, regulatory approvals, and competition from established players in the vaccine market. With a market cap of $8.12B and a beta of 1.39, Vaxcyte presents a high-growth, high-risk investment profile.
Based on FMP financials and quantitative analysis
PCVX Key Highlights
- Vaxcyte's lead vaccine candidate, VAX-24, is in Phase 1/2 clinical trials, targeting invasive pneumococcal disease and pneumonia.
- The company is developing VAX-XP to protect against emerging strains and address antibiotic resistance, showcasing their commitment to innovation.
- Vaxcyte's pipeline includes VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep, expanding their therapeutic focus.
- VAX-PG, a novel protein vaccine candidate, targets the keystone pathogen responsible for periodontitis, demonstrating their diverse approach to vaccine development.
- Vaxcyte changed its name from SutroVax, Inc. in May 2020, reflecting its evolution and strategic focus on vaccine development.
Who Are PCVX's Competitors?
PCVX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ARWR Arrowhead Pharmaceuticals, Inc. | $71.65 | -3.57% | $10.1B | 31 |
| KRYS Krystal Biotech, Inc. | $339.22 | -4.41% | $10.0B | 100 |
| ACLX Arcellx, Inc. | $115.07 | +0.02% | $6.73B | 45 |
| ALKS Alkermes plc | $51.72 | -1.90% | $8.62B | 51 |
| TGTX TG Therapeutics, Inc. | $53.96 | -1.66% | $8.26B | 70 |
| APGE Apogee Therapeutics, Inc. | $134.15 | +0.11% | $8.30B | 71 |
| HALO Halozyme Therapeutics, Inc. | $77.09 | -0.93% | $9.14B | 94 |
| BRRGF BerGenBio ASA | $97.09 | +0.00% | $9.49B | 74 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PCVX's Key Strengths?
- Innovative vaccine technology platform.
- Strong pipeline of vaccine candidates.
- Experienced management team.
- Focus on addressing unmet needs in infectious disease prevention.
What Are PCVX's Weaknesses?
- Clinical-stage company with no currently marketed products.
- Reliance on successful clinical trial outcomes.
- High research and development costs.
- Dependence on regulatory approvals.
What Could Drive PCVX Stock Higher?
- Announcement of Phase 1/2 clinical trial results for VAX-24.
- Initiation of clinical trials for VAX-XP.
- Continued progress in the development of VAX-A1 and VAX-PG.
- Potential for strategic partnerships or collaborations.
What Are the Key Risks for PCVX?
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Unfavorable clinical trial results for VAX-24 or other vaccine candidates.
- Regulatory delays or rejection of vaccine approvals.
- Competition from established vaccine manufacturers.
- High research and development costs.
- Intellectual property challenges.
What Are the Growth Opportunities for PCVX?
- Expansion of VAX-24: Vaxcyte has the opportunity to expand the use of VAX-24 beyond its current Phase 1/2 clinical trials. Positive results could lead to further clinical development and eventual commercialization, addressing a significant portion of the pneumococcal vaccine market.
- Development of VAX-XP: VAX-XP, designed to protect against emerging pneumococcal strains and address antibiotic resistance, represents a significant growth opportunity. As antibiotic resistance becomes an increasingly pressing global health concern, vaccines that can circumvent this issue will be highly valuable. Successful development and commercialization of VAX-XP could position Vaxcyte as a leader in addressing this critical need.
- Advancement of VAX-A1: The development of VAX-A1, a conjugate vaccine candidate targeting Group A Strep, offers another avenue for growth. Group A Strep infections are common and can lead to serious complications, creating a substantial market for an effective vaccine. Vaxcyte's focus on this area could lead to a valuable addition to its product portfolio.
- Commercialization of VAX-PG: VAX-PG, targeting the keystone pathogen responsible for periodontitis, represents a novel approach to addressing a widespread oral health issue. Periodontitis affects a significant portion of the adult population, creating a large potential market for a preventative vaccine. Successful development and commercialization of VAX-PG could establish Vaxcyte in a new therapeutic area.
- Strategic Partnerships: Vaxcyte can pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its vaccine candidates. Collaborations can provide access to additional resources, expertise, and distribution networks, enhancing the company's ability to bring its products to market and maximize their impact.
What Opportunities Does PCVX Have?
- Expansion of vaccine pipeline through new targets.
- Strategic partnerships with larger pharmaceutical companies.
- Growing demand for preventative healthcare solutions.
- Addressing the increasing threat of antibiotic resistance.
What Threats Does PCVX Face?
- Competition from established vaccine manufacturers.
- Unfavorable clinical trial results.
- Regulatory hurdles and delays.
- Changing market dynamics and healthcare policies.
What Are PCVX's Competitive Advantages?
- Proprietary vaccine technology platform.
- Strong intellectual property portfolio.
- Clinical trial data demonstrating efficacy.
- Experienced management team with expertise in vaccine development.
What Does PCVX Do?
Vaxcyte, Inc., formerly known as SutroVax, Inc., was founded in 2013 and is headquartered in San Carlos, California. The company is dedicated to the development of innovative protein vaccines designed to prevent and treat bacterial infectious diseases. Vaxcyte's core technology focuses on creating vaccines that offer broad protection against prevalent and emerging bacterial strains. Their lead vaccine candidate, VAX-24, is a 24-valent investigational pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials. This vaccine aims to provide comprehensive coverage against the 24 serotypes of Streptococcus pneumoniae, which are responsible for a significant portion of invasive pneumococcal disease and pneumonia cases. Beyond VAX-24, Vaxcyte is also developing VAX-XP, a vaccine designed to protect against emerging pneumococcal strains and address the growing issue of antibiotic resistance. The company's pipeline includes VAX-A1, a conjugate vaccine candidate targeting Group A Streptococcus (GAS), a bacterium responsible for various infections, including strep throat and rheumatic fever. Additionally, Vaxcyte is developing VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis, a common and serious gum infection. Vaxcyte's strategic focus on addressing unmet needs in infectious disease prevention positions it as a key player in the biotechnology sector.
What Products and Services Does PCVX Offer?
- Develop novel protein vaccines to prevent bacterial infectious diseases.
- Focus on vaccines that offer broad protection against prevalent and emerging bacterial strains.
- Conduct clinical trials to evaluate the safety and efficacy of their vaccine candidates.
- Target unmet needs in infectious disease prevention.
- Address the growing issue of antibiotic resistance through innovative vaccine design.
- Develop conjugate vaccines targeting specific bacterial pathogens.
How Does PCVX Make Money?
- Research and development of novel protein vaccines.
- Conducting clinical trials to demonstrate safety and efficacy.
- Seeking regulatory approval from agencies like the FDA.
- Commercializing approved vaccines through partnerships or direct sales.
What Industry Does PCVX Operate In?
Vaxcyte operates within the biotechnology industry, specifically focusing on vaccine development. The global vaccine market is experiencing substantial growth, driven by increasing awareness of preventative healthcare, rising prevalence of infectious diseases, and advancements in vaccine technologies. The competitive landscape includes established pharmaceutical companies and other biotechnology firms developing vaccines for various diseases. Vaxcyte differentiates itself through its novel protein vaccine technology and its focus on addressing unmet needs in bacterial infectious diseases. The company's success depends on its ability to navigate the complex regulatory environment and effectively commercialize its vaccine candidates.
Who Are PCVX's Key Customers?
- Healthcare providers (doctors, hospitals, clinics).
- Public health organizations (government agencies).
- Individuals seeking preventative healthcare.
- Pharmacies and distributors.
How Vaxcyte, Inc. Is Valued
Relative to its peer group, PCVX's quantitative score of 53/100 is roughly in line with the peer average of 59/100.
Company Profile
Vaxcyte, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Carlos, US. The company is led by CEO Grant E. Pickering. PCVX has traded publicly since 2020.
F-Score 1/9Financial Health
Vaxcyte, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 12.42 places it in the safe zone, indicating low near-term bankruptcy risk.
FY2026 estForward Outlook
Wall Street analysts project Vaxcyte, Inc. revenue of about $25.0M for fiscal 2026, with EPS near $-8.38. The estimate reflects 5 contributing analysts.
Net buyingInsider Activity
Over the past six months, Vaxcyte, Inc. insiders filed 29 SEC Form 4 transactions — 15 sales and 14 purchases. On net that is roughly 38K shares acquired (about $1.1M) — insiders putting money in tends to read as conviction.
PCVX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Vaxcyte's recent insider buying suggests confidence in the company's future prospects, mirroring situations like executives loading up on Tesla before major milestones. The community buzz is largely positive, focusing on potential pipeline breakthroughs. Market perception sees Vaxcyte as a key player in next-gen vaccine tech. Recent developments highlight increasing partnerships and collaborations, signaling industry validation.
- Vaxcyte's innovative vaccine platform is attracting significant attention, reminiscent of Moderna's early days. Community sentiment reflects strong belief in the company's ability to disrupt the vaccine market. The market is viewing Vaxcyte as a high-growth potential biotech. New data releases are being interpreted as very promising by key opinion leaders.
Bear Case
- Competition in the vaccine space is intensifying, putting pressure on Vaxcyte to deliver results quickly, much like the crowded EV market. Community sentiment shows some worry about the company's cash burn rate. The market is aware of the high regulatory hurdles involved in vaccine development. There are concerns about the scalability of Vaxcyte's manufacturing process if their vaccines are approved.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
PCVX Latest News
-
Vaxcyte Inc (PCVX) Is A Hidden Multibagger Stock To Buy Now
Yahoo! Finance: PCVX News · Jul 3, 2026
-
10 Health Care Stocks With Whale Alerts In Today’s Session
benzinga · Jun 29, 2026
-
Vaxcyte Insider Sold Shares Worth $1,338,270, According to a Recent SEC Filing
MT Newswires · Jun 29, 2026
-
Vaxcyte (PCVX) Doses Its First Patient in a Trial for a Disease With No Existing Vaccine
Yahoo! Finance: PCVX News · Jun 22, 2026
PCVX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PCVX.
Price Targets
Consensus target: $89.00
PCVX MoonshotScore
What does this score mean?
The MoonshotScore rates PCVX 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Latest News
Vaxcyte Inc (PCVX) Is A Hidden Multibagger Stock To Buy Now
10 Health Care Stocks With Whale Alerts In Today’s Session
Vaxcyte Insider Sold Shares Worth $1,338,270, According to a Recent SEC Filing
Vaxcyte (PCVX) Doses Its First Patient in a Trial for a Disease With No Existing Vaccine
Latest Vaxcyte, Inc. Analysis
Leadership: Grant E. Pickering
CEO
Grant E. Pickering serves as the Chief Executive Officer of Vaxcyte, Inc. His career spans several leadership roles within the biotechnology and pharmaceutical industries. Prior to joining Vaxcyte, Pickering held significant positions at leading healthcare companies, contributing to strategic planning, business development, and product commercialization. His experience includes a deep understanding of vaccine development, clinical trials, and regulatory affairs. Pickering's expertise is instrumental in guiding Vaxcyte's strategic direction and driving the company's growth.
Track Record: Under Grant Pickering's leadership, Vaxcyte has advanced its lead vaccine candidate, VAX-24, through Phase 1/2 clinical trials. He has overseen the expansion of the company's pipeline to include VAX-XP, VAX-A1, and VAX-PG, targeting additional infectious diseases. Pickering has also been instrumental in securing funding and establishing strategic partnerships to support Vaxcyte's research and development efforts.
Vaxcyte, Inc. Healthcare Stock: Key Questions Answered
What does the AI Score mean for PCVX?
PCVX holds an AI Score of 53/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. Vaxcyte, Inc. is a clinical-stage biotechnology company focused on developing novel protein vaccines for bacterial infectious diseases. Their lead candidate, VAX-24, targets pneumococcal disease …
What does Vaxcyte, Inc. do?
Vaxcyte, Inc. is a clinical-stage biotechnology company focused on developing novel protein vaccines to prevent or treat bacterial infectious diseases. Their lead vaccine candidate, VAX-24, is a 24-valent investigational pneumococcal conjugate vaccine currently in Phase 1/2 clinical trials, targeting invasive pneumococcal disease and pneumonia.
What do analysts say about PCVX stock?
Analyst coverage of Vaxcyte (PCVX) reflects a focus on its clinical pipeline and the potential of its vaccine candidates. Key valuation metrics include market capitalization and enterprise value, which are used to assess the company's overall worth. Growth considerations center on the successful completion of clinical trials, regulatory approvals, and the commercial potential of Vaxcyte's vaccines.
What are the main risks for PCVX?
Vaxcyte faces several key risks inherent to the biotechnology industry. Clinical trial risk is significant, as unfavorable results for VAX-24 or other vaccine candidates could negatively impact the company's valuation. Regulatory risk is also a factor, as delays or rejection of vaccine approvals could hinder commercialization efforts.
How does Vaxcyte, Inc. navigate regulatory approval processes?
Vaxcyte, Inc. navigates regulatory approval processes by adhering to stringent guidelines set forth by regulatory agencies such as the FDA in the United States. The company meticulously designs and executes clinical trials to demonstrate the safety and efficacy of its vaccine candidates. Vaxcyte maintains rigorous documentation and quality control processes throughout the development and manufacturing stages.
What is Vaxcyte, Inc.'s drug pipeline status?
Vaxcyte, Inc.'s drug pipeline includes several vaccine candidates in various stages of development. The lead candidate, VAX-24, is currently in Phase 1/2 clinical trials, targeting invasive pneumococcal disease and pneumonia. Vaxcyte is also developing VAX-XP to protect against emerging pneumococcal strains and address antibiotic resistance.
What are the key factors to evaluate for PCVX?
Vaxcyte, Inc. (PCVX) holds an AI score of 53/100 (moderate). Analysts target $89.00 (+58%). Not financial advice.
How frequently does PCVX data refresh on this page?
PCVX's price was last updated on Jul 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven PCVX's recent stock price performance?
Vaxcyte, Inc. (PCVX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative vaccine technology platform. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available company data and may be subject to change.
- Clinical trial outcomes are inherently uncertain and can impact future results.